<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14352">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920047</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FAC-CT-102</org_study_id>
    <nct_id>NCT02920047</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan/Amlodipine and Co-administration of Fimasartan and Amlodipine in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety when administrated
      Fimasartan/Amlodipine and when co-administrated Fimasartan and Amlodipine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, 3x3 partial replicated crossover study to evaluate the
      pharmacokinectics and safety/tolerability. Within each period, randomized subjects will be 2
      dosing regimens with a fixed dose combination of Fimasartan/Amlodipine and co-administration
      of Fimasartan and Amlodipine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUClast of Fimasartan, Amlodipine</measure>
    <time_frame>Time Frame: 0~144 hour after medication</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)
There will be a washout of 14 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)
There will be a washout of 14 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequency C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)
There will be a washout of 14 days between the each period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan/Amlodipine</intervention_name>
    <description>Treatment B</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequency C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan + Amlodipine</intervention_name>
    <description>Treatment A</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequency C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male 19-50 years of age.

          2. Body mass index (BMI) ≥ 18 and ≤ 27 kg/m2 at screening.

          3. Medically healthy with no clinically significant medical history.

          4. Understands the study procedures in the Informed consent form (ICF), and be willing
             and able to comply with the protocol.

        Exclusion Criteria:

          1. History or presence of clinically significant medical or psychiatric condition or
             disease.

          2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV).

          3. Seated blood pressure is less than 100/65 mmHg or greater than 140/90 mmHg at
             screening.

          4. Plasma donation within a month prior to the first dose of study drug.

          5. Participation in another clinical trial within 3 months prior to the first dose of
             study drug(s).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 3, 2017</lastchanged_date>
  <firstreceived_date>September 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
